ECQ0.F Neurizon Therapeutics Limited

Healthcare Biotechnology Frankfurt Exchange
0.0295 EUR
Close of Nov 12, 2026
0.0235 0.0680
Market cap
EUR 25.2M
P/E
-
P/B
3.27x
ROE
-84.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is ECQ0.F undervalued?

Graham number

The Graham number of Neurizon Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neurizon Therapeutics Limited fundamental analysis

No fundamental analysis for Neurizon Therapeutics Limited yet.

Neurizon Therapeutics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its…

Full company profile